<DOC>
	<DOC>NCT00490711</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of paclitaxel and carboplatin followed by gemcitabine and carboplatin therapy for patients with epithelial ovarian cancer.</brief_summary>
	<brief_title>Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically verified epithelial ovarian cancer FIGO stage IIIIV Patients with measurable disease. RECIST criteria with GCIG modifications will be used for response and for progression assessment. Lesions serving as measurable disease must have the longest diameter of greater than or equal to 20 mm as measured with conventional techniques or greater than or equal to 10 mm with spiral CT scan. Lesions measured by physical examination must have a longest diameter of greater than or equal to 20 mm. Ovarian tumors with low malignant potential (borderline tumors) Nonepithelial ovarian or mixed epithelial. non epithelial tumors (e.g. mixed Mullerian tumors) Time between definitive surgery and enrollment into the study is greater than 6 weeks Patients who have received previous chemotherapy or radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>